Email Templates
Write to Pharmac
Click on the buttons to copy the email addresses and message below then paste into the body of an email, add in the information needed and personalise if you would like, including things like photos and about your experience with myeloma, then send.
Email addresses
Click the buttons to copy individual email addresses or choose to copy multiple addresses to send a group email, then paste it into the To: field of your email using Ctrl + V or right click / select Paste.
SARAH FITT
Pharmac Chief Executive
DR DAVID HUGHES
Director Advice and Assessment and Chief Medical Officer
DR PETER BRAMLEY
Acting Chair
GERALDINE MacGIBBON
Director, Pharmaceuticals
DR ROBYN MANUEL
Pharmac Consumer Advisory Committee Chair
TREVOR SIMPSON
Kaituruki Māori – Director Māori
DR NICOLA NGAWATI
Director Equity and Engagement
KATHRYN MCINTEER
Director of Corporate Services and Financial Services
MICHAEL JOHNSON
Director Strategy, Policy and Performance
Click the buttons to copy individual email addresses or choose to copy multiple addresses to send a group email, then paste it into the To: field of your email using Ctrl + V or right click / select Paste.
Letter to Pharmac
Paste text into the body of an email after you’ve clicked this button and personalise your email before sending.
Dear [Name]
[My name is (name) and I have multiple myeloma OR /my (relationship to you, eg mum, husband) has multiple myeloma.]
I am writing to you about Daratumumab and carfilzomib, multiple myeloma treatments on the Options for Investment list.
As you know, there is a desperate need for better myeloma treatments in New Zealand. I know Pharmac have these myeloma treatments on the Options for Investment list, and I thank you for that.
The situation is becoming more desperate because not only are we lacking modern myeloma treatments, New Zealand myeloma patients are now missing out on trials because we can not access standard of care medicines like daratumumab. We will risk future medicines not being registered here too.
I ask you to fund daratumumab and carfilzomib, which are on the OFI list.
Being on the OFI alone is not enough. I am concerned about where on the list the myeloma treatments are. I therefore also urge you to please put daratumumab and carfilzomib to the top of the Options for Investment list so they have a realistic chance of being funded.
Yours sincerely,
[Name]
Paste text into the body of an email after you’ve clicked this button and personalise your email before sending.
